European Medicines Agency Accepts Application Seeking New Indication For Pfizer Inc. (PFE)'s Prevenar 13®1 For Prevention Of Pneumococcal Pneumonia In Adults
8/7/2014 11:07:00 AM
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency (EMA) has accepted Pfizer’s application seeking to expand the indication for Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes contained in the vaccine.
“Pneumococcal pneumonia continues to be a serious health problem, causing significant illness and mortality in older adults,” said Dr. Emilio A. Emini, senior vice president, Vaccine Research and Development, Pfizer. “The results of the Community-Acquired Pneumonia Trial in Adults study underscore the potential benefits of Prevenar 13 in preventing disease in this age group.”
Help employers find you! Check out all the jobs and post your resume.
comments powered by